Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance

Background/Objectives: Pasireotide (PAS) is a somatostatin receptor ligand (SRL) used to treat acromegaly, a chronic condition caused by excess growth hormone. While it offers significant benefits as a second-line treatment for uncontrolled acromegaly, its use raises major concerns due to hyperglyce...

Full description

Bibliographic Details
Main Authors: Ioana Rada Popa Ilie, Carmen Maximiliana Dobrea, Anca Butuca, Calin Homorodean, Claudiu Morgovan, Andreea Loredana Vonica-Tincu, Felicia Gabriela Gligor, Steliana Ghibu, Adina Frum
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceuticals
Subjects:
somatostatin receptor ligand
pasireotide
pharmacovigilance
EudraVigilance
real-world evidence
Online Access:https://www.mdpi.com/1424-8247/17/12/1631

Internet

https://www.mdpi.com/1424-8247/17/12/1631

Similar Items